Questcor Pharmaceuticals (Nasdaq:QCOR) is trading at unusually high volume Wednesday with 3.6 million shares changing hands. It is currently at two times its average daily volume and trading up $4.17 (+9.9%).
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Questcor Pharmaceuticals (Nasdaq: QCOR) is trading at unusually high volume Wednesday with 3.6 million shares changing hands. It is currently at two times its average daily volume and trading up $4.17 (+9.9%) at $46.28 as of 1:30 p.m. ET.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Questcor has a market cap of $2.19 billion and is part of the health care sector and drugs industry. Shares are up 57.6% year to date as of the close of trading on Tuesday. Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. The company has a P/E ratio of 11.4, below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Questcor as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. You can view the full Questcor Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..